ATI has been in the back cupboard for a long while Speckled. But the company has been paying US specialists to sell the business as a partnership or asset for a while now. It first engaged US-based consultants to support the commercialisation and potential sale or partnership of its OrthoATI business as early as 2021. More my point is what have they being doing all this time (other than earning fees)?
It's another little disappointment with execution delivery is my point. PA and Prf. MZ's time would have been better spent, for shareholder purposes, securing a decent sale, or even better partnership in the US was more my point, rather than private ventures, since funded in part by OCC shareholder capital. The company would not have needed to tap the market for capital in its US/EU expansionary thrust, and the stock certainly would not be below $1.
Anyway, a very comprehensive update on Remplir in the US. Thanks @FreeFromStyle for the written summary above.
Add to My Watchlist
What is My Watchlist?
